Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

NCT06838286 · clinicaltrials.gov ↗

RECRUITING

Status

10000

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: SGLT2 inhibitor
DRUG: Thiazolidinedione
DRUG: DPP-4 inhibitor

Sponsor

Chong Kun Dang Pharmaceutical